Hualan Biological Vaccine Inc.

301207

CNE1000058J9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
21.28 ^CNY	-8.87%		-6.13%	-23.45%

Apr. 25	Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 01	Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023	CI

Hualan Biological Bacterin Inc. Announces Implementation of Final Profit Distribution Plan of A Shares for 2022, Payable on 07 June 2023

May 31, 2023 at 03:42 pm EDT

Hualan Biological Bacterin Inc. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 3.00000000. Record date: 06 June 2023, Ex-date: 07 June 2023, Payment date: 07 June 2023.

Latest news about Hualan Biological Vaccine Inc.

Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023	Apr. 01	CI
Hualan Biological Vaccine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Certain A Shares of Hualan Biological Bacterin Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024.	Feb. 17	CI
Hualan Biological Bacterin Inc. has Changed its Name to Hualan Biological Vaccine Inc	Nov. 16	CI
Hualan Biological Vaccine Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Hualan Biological Bacterin Inc.(XSEC:301207) added to S&P Global BMI Index	23-09-18	CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Hualan Biological Bacterin Inc. Announces Implementation of Final Profit Distribution Plan of A Shares for 2022, Payable on 07 June 2023	23-05-31	CI
Hualan Biological Bacterin Inc. Approves Cash Dividend for the Year 2022	23-04-24	CI
Hualan Biological Bacterin Inc. Announces Board Elections	23-04-24	CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Hualan Biological Bacterin to Return to Profit in Q1	23-04-10	MT
Hualan Biological Bacterin Inc. Proposes Final Cash Dividend for 2022	23-03-30	CI
Hualan Biological Bacterin Gets Certification for Tetanus Vaccine	23-02-28	MT
Certain A Shares of Hualan Biological Bacterin Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2023.	23-02-17	CI
Hualan Biological Bacterin Registers Freeze-Dried Human Rabies Vaccine	23-02-01	MT
Hualan Biological Bacterin Inc.(SZSE:301207) added to Shenzhen Stock Exchange Component Index	22-12-12	CI
Hualan Biological Bacterin Inc.(SZSE:301207) added to Shenzhen Stock Exchange Component A Share Index	22-12-12	CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
China's Sept factory activity set for third straight monthly contraction:Reuters poll	22-09-29	RE
Hualan Biological Bacterin Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Hualan Biological Bacterin Inc. Announces Final Dividend on Share A for 2021, Payable on June 16, 2022	22-06-08	CI
Hualan Biological Bacterin Inc. Approves Cash Dividend for the Year 2021	22-04-29	CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI

Chart Hualan Biological Vaccine Inc.

Duration

Period

More charts

Company Profile

Hualan Biological Vaccine Inc, formerly Hualan Biological Bacterin Inc, is a China-based company principally engaged in the research, development, production and sales of human vaccines. The Company's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The Company's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The Company's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hualan Biological Vaccine Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.28 CNY

Average target price

33.2 CNY

Spread / Average Target

+56.02%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
HUALAN BIOLOGICAL VACCINE INC.	-23.45%	1.76B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals

Hualan Biological Vaccine Inc.

Equities

301207

CNE1000058J9

Pharmaceuticals

Hualan Biological Bacterin Inc. Announces Implementation of Final Profit Distribution Plan of A Shares for 2022, Payable on 07 June 2023

Latest news about Hualan Biological Vaccine Inc.

Chart Hualan Biological Vaccine Inc.

Company Profile

Income Statement Evolution

Ratings for Hualan Biological Vaccine Inc.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals